Dataset Information


Targeting the centriolar replication factor STIL synergizes with DNA damaging agents for treatment of ovarian cancer.

ABSTRACT: Advanced ovarian cancer is an incurable disease. Thus, novel therapies are required. We wished to identify new therapeutic targets for ovarian cancer. ShRNA screen performed in 42 ovarian cancer cell lines identified the centriolar replication factor STIL as an essential gene for ovarian cancer cells. This was verified in-vivo in orthotopic human ovarian cancer mouse models. STIL depletion by administration of siRNA in neutral liposomes resulted in robust anti-tumor effect that was further enhanced in combination with cisplatin. Consistent with this finding, STIL depletion enhanced the extent of DNA double strand breaks caused by DNA damaging agents. This was associated with centrosomal depletion, ongoing genomic instability and enhanced formation of micronuclei. Interestingly, the ongoing DNA damage was not associated with reduced DNA repair. Indeed, we observed that depletion of STIL enhanced canonical homologous recombination repair and increased BRCA1 and RAD51 foci in response to DNA double strand breaks. Thus, inhibition of STIL significantly enhances the efficacy of DNA damaging chemotherapeutic drugs in treatment of ovarian cancer.

SUBMITTER: Rabinowicz N 

PROVIDER: S-EPMC5432342 | BioStudies | 2017-01-01

REPOSITORIES: biostudies

Similar Datasets

1000-01-01 | S-EPMC3243611 | BioStudies
2015-01-01 | S-EPMC4319975 | BioStudies
| S-EPMC6522276 | BioStudies
1000-01-01 | S-EPMC6006521 | BioStudies
| S-EPMC7183410 | BioStudies
1000-01-01 | S-EPMC4794602 | BioStudies
2015-01-01 | S-EPMC4632285 | BioStudies
2010-01-01 | S-EPMC2912507 | BioStudies
| S-EPMC7519908 | BioStudies
1000-01-01 | S-EPMC4394248 | BioStudies